




RealRate

PHARMACEUTICAL 2020

Magenta Therapeutics Inc.
Rank 178 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Magenta Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Magenta Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 231% points. The greatest weakness of Magenta Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 116% points.

The company's Economic Capital Ratio, given in the ranking table, is -172%, being 131% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	149,843
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,115
Liabilities, Non-Current	0
Other Assets	1,780
Other Compr. Net Income	16
Other Expenses	0
Other Liabilities	6,206
Other Net Income	0
Property and Equipment	9,891
Research and Development	59,208
Revenues	6,200
Selling, General and Administrative Expense	23,761

Output Variable	Value in 1000 USD
Assets	161,514
Liabilities	20,321
Expenses	82,969
Stockholders Equity	141,193
Net Income	-76,769
Comprehensive Net Income	-76,761
Economic Capital Ratio	-172%